Literature DB >> 18497311

Triple twist theory of rho inhibition by the angiotensin II type 2 receptor.

Satoru Eguchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18497311      PMCID： PMC2749212          DOI： 10.1161/CIRCRESAHA.108.177295

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  28 in total

1.  Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II.

Authors:  Haruhiko Ohtsu; Mizuo Mifune; Gerald D Frank; Shuichi Saito; Tadashi Inagami; Shokei Kim-Mitsuyama; Yoh Takuwa; Terukatsu Sasaki; Jeffrey D Rothstein; Hiroyuki Suzuki; Hidekatsu Nakashima; Elethia A Woolfolk; Evangeline D Motley; Satoru Eguchi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-06-30       Impact factor: 8.311

Review 2.  Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells.

Authors:  Haruhiko Ohtsu; Hiroyuki Suzuki; Hidekatsu Nakashima; Sudhir Dhobale; Gerald D Frank; Evangeline D Motley; Satoru Eguchi
Journal:  Hypertension       Date:  2006-08-21       Impact factor: 10.190

Review 3.  Rho kinases in cardiovascular physiology and pathophysiology.

Authors:  Gervaise Loirand; Patrice Guérin; Pierre Pacaud
Journal:  Circ Res       Date:  2006-02-17       Impact factor: 17.367

Review 4.  Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II.

Authors:  László Hunyady; Kevin J Catt
Journal:  Mol Endocrinol       Date:  2005-09-01

5.  Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats.

Authors:  Carmine Savoia; Fatiha Tabet; Guoying Yao; Ernesto L Schiffrin; Rhian M Touyz
Journal:  J Hypertens       Date:  2005-05       Impact factor: 4.844

6.  The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy.

Authors:  Angelo D'Amore; M Jane Black; Walter G Thomas
Journal:  Hypertension       Date:  2005-11-14       Impact factor: 10.190

7.  Induction of apoptosis by the Ste20-like kinase SLK, a germinal center kinase that activates apoptosis signal-regulating kinase and p38.

Authors:  Wen Hao; Tomoko Takano; Julie Guillemette; Joan Papillon; Guohui Ren; Andrey V Cybulsky
Journal:  J Biol Chem       Date:  2005-11-29       Impact factor: 5.157

8.  ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II.

Authors:  Haruhiko Ohtsu; Peter J Dempsey; Gerald D Frank; Eugen Brailoiu; Sadaharu Higuchi; Hiroyuki Suzuki; Hidekatsu Nakashima; Kunie Eguchi; Satoru Eguchi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-07-13       Impact factor: 8.311

9.  AT2 receptors cross talk with AT1 receptors through a nitric oxide- and RhoA-dependent mechanism resulting in decreased phospholipase D activity.

Authors:  Bradley T Andresen; Kuntala Shome; Edwin K Jackson; Guillermo G Romero
Journal:  Am J Physiol Renal Physiol       Date:  2004-11-30

Review 10.  Physiological role of ROCKs in the cardiovascular system.

Authors:  Kensuke Noma; Naotsugu Oyama; James K Liao
Journal:  Am J Physiol Cell Physiol       Date:  2006-03       Impact factor: 4.249
View more
  2 in total

1.  Angiotensin II type-1 receptor regulates RhoA and Rho-kinase/ROCK activation via multiple mechanisms. Focus on "Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells".

Authors:  Keita Kimura; Satoru Eguchi
Journal:  Am J Physiol Cell Physiol       Date:  2009-09-09       Impact factor: 4.249

2.  Valsartan Upregulates Kir2.1 in Rats Suffering from Myocardial Infarction via Casein Kinase 2.

Authors:  Xinran Li; Hesheng Hu; Ye Wang; Mei Xue; Xiaolu Li; Wenjuan Cheng; Yongli Xuan; Jie Yin; Na Yang; Suhua Yan
Journal:  Cardiovasc Drugs Ther       Date:  2015-06       Impact factor: 3.727
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.